ketendoКлиническая и экспериментальная тиреоидологияClinical and experimental thyroidology1995-54722310-3787Endocrinology Research Centre10.14341/ket12759ketendo-12759Research ArticleНаучный обзорReviewЛекарственные формы левотироксина натрия. Есть ли место новому в лечении гипотиреоза?Drug forms of levothyroxine. Is there room for innovation in hypothyroidism treatment?https://orcid.org/0000-0003-2283-8958КолпаковаЕ. А.KolpakovaE. A.

Колпакова Евгения Александровна

117292, Москва, ул. Дмитрия Ульянова, д. 11 

eLibrary SPIN: 5040-8628

Evgenia A. Kolpakova, MD

Dmitry Ulyanov street 11, 117292, Moscow

eLibrary SPIN: 5040-8628

colpakova.ev@mail.ruhttps://orcid.org/0000-0001-8838-8908ВознесенскаяА. А.VoznesenskayaA. A.

Вознесенская Анастасия Александровна 

Москва

Anastasia А. Voznesenskaya, MD

Moscow

voznesenskaya.A.A@yandex.ruhttps://orcid.org/0009-0001-6204-4231ФролковаН. В.FrolkovaN. V.

Фролкова Надежда Викторовна

Москва

Nadezhda V. Frolkova, MD

Moscow

nadya.frolkova@mail.ruhttps://orcid.org/0000-0002-8520-8702ТрошинаЕ. А.TroshinaE. A.

Трошина Екатерина Анатольевна, доктор медицинских наук, профессор, член-корреспондент РАН 

Москва

eLibrary SPIN: 8821-8990

 

Ekaterina A. Troshina, MD, PhD, professor, corresponding member of the Russian Academy of Sciences

Moscow

eLibrary SPIN: 8821-8990

troshina@inbox.ruНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation202214072023184413Copyright © Колпакова Е.А., Вознесенская А.А., Фролкова Н.В., Трошина Е.А., 20232023Колпакова Е.А., Вознесенская А.А., Фролкова Н.В., Трошина Е.А.Kolpakova E.A., Voznesenskaya A.A., Frolkova N.V., Troshina E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.cet-endojournals.ru/jour/article/view/12759

Левотироксин натрия широко применяется во всем мире для лечения заболеваний, сопровождающихся сниженной функцией щитовидной железы. Несмотря на хорошо известные особенности фармакокинетики и фармакодинамики левотироксина натрия, не всем пациентам, принимающим его в таблетированной форме, удается достичь индивидуальных целей лечения. Среди основных причин неэффективности терапии — неудобный режим приема препарата с необходимостью выдерживать временные интервалы перед едой и приемом других лекарственных средств, а также целый ряд желудочно-кишечных заболеваний, влияющих на биодоступность левотироксина натрия. Данное обстоятельство способствовало появлению исследований, направленных на поиск новых лекарственных форм левотироксина, обладающих большими преимуществами с точки зрения достижения клинического эффекта в сравнении с таблетированной формой. В настоящем обзоре приведены последние данные об использовании новых лекарственных форм левотироксина. Необходимо дальнейшее проведение крупных клинических испытаний для более обоснованного и широкого использования новых лекарственных форм левотироксина в клинической практике.

Levothyroxine steadily maintains its position as the «gold standard» in the treatment of hypothyroidism. Despite the possibility of step-by-step tableted dose titration of levothyroxine, the results of many studies reliably point to the fact that a significant number of patients do not reach the target level of thyroid hormone. One of the main reasons for the therapy ineffectiveness is the inconvenience of levothyroxine sodium regimen for many patients, associated with the need to observe certain time intervals before meals and other medications. The above-mentioned factors have stimulated a number of studies aimed at developing new dosage forms with significant advantages in the pharmacokinetics and pharmacodynamics of drugs. The review provides the latest data on the new dosage forms of levothyroxine. Further large-scale clinical trials are needed for a more reasonable and widespread use of new dosage forms of levothyroxine in clinical practice.

левотироксин натрияпервичный гипотиреозвторичный гипотиреозхронический аутоиммунный тиреоидитлекарственные формыlevothyroxineprimary hypothyroidismsecondary hypothyroidismchronic autoimmune thyroiditisdosage formsРабота выполнена в рамках государственного задания № 123021300097-0 «Гормонально-метаболические и молекулярно-клеточные характеристики заболеваний щитовидной железы как основа для разработки инновационных методов диагностики, лечения и профилактики».ReferencesJonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751. doi: https://doi.org/10.1089/thy.2014.0028Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751. doi: https://doi.org/10.1089/thy.2014.0028Eligar V, Taylor PN, Okosieme OE, et al. Thyroxine replacement: a clinical endocrinologist’s viewpoint. Ann Clin Biochem. 2016;53(4):421-433. doi: https://doi.org/10.1177/0004563216642255Eligar V, Taylor PN, Okosieme OE, et al. Thyroxine replacement: a clinical endocrinologist’s viewpoint. Ann Clin Biochem. 2016;53(4):421-433. doi: https://doi.org/10.1177/0004563216642255Virili C, Trimboli P, Centanni M. Novel thyroxine formulations: a further step toward precision medicine. Endocrine. 2019;66(1):87-94. doi: https://doi.org/10.1007/s12020-019-02049-xVirili C, Trimboli P, Centanni M. Novel thyroxine formulations: a further step toward precision medicine. Endocrine. 2019;66(1):87-94. doi: https://doi.org/10.1007/s12020-019-02049-xCastellana M, Castellana C, Giovanella L, Trimboli P. Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy? Endocrine. 2020;67(2):281-290. doi: https://doi.org/10.1007/s12020-019-02185-4Castellana M, Castellana C, Giovanella L, Trimboli P. Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy? Endocrine. 2020;67(2):281-290. doi: https://doi.org/10.1007/s12020-019-02185-4Моргунова Т.Б., Фадеев В.В. Заместительная терапия гипотиреоза препаратами тиреоидных гормонов — один гормон или два? // Проблемы Эндокринологии. — 2005. — Т. 51. — №1. — С. 53-56. doi: https://doi.org/10.14341/probl200551153-56Morgunova ТВ, Fadeyev VV. Replacement therapy for hypothyroidism with thyroid hormonal drugs: one or two hormones? Problems of Endocrinology. 2005;51(1):53-56. (In Russ.). doi: https://doi.org/10.14341/probl200551153-56Bertoncini CW, Palacios MJC, Fritz MC, et al. Levothyroxine bioequivalence study and its narrow therapeutic index: comparative bioavailability results between two formulations available in Latin America. Adv Ther. 2023;40(4):1644-1654. doi: https://doi.org/10.1007/s12325-022-02352-6Bertoncini CW, Palacios MJC, Fritz MC, et al. Levothyroxine bioequivalence study and its narrow therapeutic index: comparative bioavailability results between two formulations available in Latin America. Adv Ther. 2023;40(4):1644-1654. doi: https://doi.org/10.1007/s12325-022-02352-6Charles BY, Harington R, Barger G. The constitution and synthesis of thyroxine. Nature. 1927;120(3013):170. doi: https://doi.org/10.1038/120170a0Charles BY, Harington R, Barger G. The constitution and synthesis of thyroxine. Nature. 1927;120(3013):170. doi: https://doi.org/10.1038/120170a0Hennessey JV. The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine. 2017;55(1):6-18. doi: https://doi.org/10.1007/s12020-016-1199-8Hennessey JV. The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine. 2017;55(1):6-18. doi: https://doi.org/10.1007/s12020-016-1199-8Tanguay M, Girard J, Scarsi C, et al. Pharmacokinetics and Comparative Bioavailability of a Levothyroxine Sodium Oral Solution and Soft Capsule. Clin Pharmacol Drug Dev. 2019;8(4):521-528. doi: https://doi.org/10.1002/cpdd.608Tanguay M, Girard J, Scarsi C, et al. Pharmacokinetics and Comparative Bioavailability of a Levothyroxine Sodium Oral Solution and Soft Capsule. Clin Pharmacol Drug Dev. 2019;8(4):521-528. doi: https://doi.org/10.1002/cpdd.608Virili C, Antonelli A, Santaguida MG, et al. Gastrointestinal malabsorption of thyroxine. Endocr Rev. 2018;40(1):118-136. doi: https://doi.org/10.1210/er.2018-00168Virili C, Antonelli A, Santaguida MG, et al. Gastrointestinal malabsorption of thyroxine. Endocr Rev. 2018;40(1):118-136. doi: https://doi.org/10.1210/er.2018-00168Mateo RCI, Hennessey JV. Thyroxine and treatment of hypothyroidism: seven decades of experience. Endocrine. 2019;66(1):10-17. doi: https://doi.org/10.1007/s12020-019-02006-8Mateo RCI, Hennessey JV. Thyroxine and treatment of hypothyroidism: seven decades of experience. Endocrine. 2019;66(1):10-17. doi: https://doi.org/10.1007/s12020-019-02006-8Soiza RL, Donaldson AIC, Myint PK. Vaccine against arteriosclerosis: an update. Ther Adv Vaccines. 2018;9(6):259-261. doi: https://doi.org/10.1177/httpsSoiza RL, Donaldson AIC, Myint PK. Vaccine against arteriosclerosis: an update. Ther Adv Vaccines. 2018;9(6):259-261. doi: https://doi.org/10.1177/httpsHays MT. Thyroid hormone and the gut. Endocr Res. 1988;14(2-3):203-224. doi: https://doi.org/10.3109/07435808809032986Hays MT. Thyroid hormone and the gut. Endocr Res. 1988;14(2-3):203-224. doi: https://doi.org/10.3109/07435808809032986Sachmechi I, Reich DM, Aninyei M, et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345-349. doi: https://doi.org/10.4158/EP.13.4.345Sachmechi I, Reich DM, Aninyei M, et al. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract. 2007;13(4):345-349. doi: https://doi.org/10.4158/EP.13.4.345Movaffagh J, Hadizadeh F, Khodaverdi E, et al. Preparation and in vitro evaluation of injectable formulations of levothyroxine sodium using in situ forming hydrogel temperature-responsive systems based on PLA-PEG-PLA and PLGA-PEG-PLGA triblock copolymers. Iran J Basic Med Sci. 2022;25(3):341-351. doi: https://doi.org/10.22038/ijbms.2022.62576.13842Movaffagh J, Hadizadeh F, Khodaverdi E, et al. Preparation and in vitro evaluation of injectable formulations of levothyroxine sodium using in situ forming hydrogel temperature-responsive systems based on PLA-PEG-PLA and PLGA-PEG-PLGA triblock copolymers. Iran J Basic Med Sci. 2022;25(3):341-351. doi: https://doi.org/10.22038/ijbms.2022.62576.13842Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. 2005;90(1):124-127. doi: https://doi.org/10.1210/jc.2004-1306Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. 2005;90(1):124-127. doi: https://doi.org/10.1210/jc.2004-1306Cappelli C, Castello R, Marini F, et al. Adherence to levothyroxine treatment among patients with hypothyroidism: A northeastern Italian survey. Front Endocrinol (Lausanne). 2018;(9):1-5. doi: https://doi.org/10.3389/fendo.2018.00699Cappelli C, Castello R, Marini F, et al. Adherence to levothyroxine treatment among patients with hypothyroidism: A northeastern Italian survey. Front Endocrinol (Lausanne). 2018;(9):1-5. doi: https://doi.org/10.3389/fendo.2018.00699Hays MT. Localization of human thyroxine absorption. Thyroid. 1991;1(3):241-248. doi: https://doi.org/10.1089/thy.1991.1.241Hays MT. Localization of human thyroxine absorption. Thyroid. 1991;1(3):241-248. doi: https://doi.org/10.1089/thy.1991.1.241McLeod JG. Clinical and experimental neurology. Med J Aust. 1984;140(7):437-437. doi: https://doi.org/10.5694/j.1326-5377.1984.tb108124.xMcLeod JG. Clinical and experimental neurology. Med J Aust. 1984;140(7):437-437. doi: https://doi.org/10.5694/j.1326-5377.1984.tb108124.xRuchała M, Bossowski A, Brzózka MM, et al. Liquid levothyroxine improves thyroid control in patients with different hypothyroidism aetiology and variable adherence — case series and review. Endokrynol Pol. 2022;73(5):893-902. doi: https://doi.org/10.5603/EP.a2022.0078Ruchała M, Bossowski A, Brzózka MM, et al. Liquid levothyroxine improves thyroid control in patients with different hypothyroidism aetiology and variable adherence — case series and review. Endokrynol Pol. 2022;73(5):893-902. doi: https://doi.org/10.5603/EP.a2022.0078Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787-1795. doi: https://doi.org/10.1056/NEJMoa043903Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787-1795. doi: https://doi.org/10.1056/NEJMoa043903Jojima T, Shinzawa T, Ohira E, et al. Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intolerance. Endocr J. 2022;69(8):941-945. doi: https://doi.org/10.1507/endocrj.EJ21-0656Jojima T, Shinzawa T, Ohira E, et al. Switching from the tablet to the powder formulation of levothyroxine corrects severe hypothyroidism in a patient with lactose intolerance. Endocr J. 2022;69(8):941-945. doi: https://doi.org/10.1507/endocrj.EJ21-0656Cassio A, Monti S, Rizzello A, et al. Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism. J Pediatr. 2013;162(6):1264-1269.e2. doi: https://doi.org/10.1016/j.jpeds.2012.11.070Cassio A, Monti S, Rizzello A, et al. Comparison between liquid and tablet formulations of levothyroxine in the initial treatment of congenital hypothyroidism. J Pediatr. 2013;162(6):1264-1269.e2. doi: https://doi.org/10.1016/j.jpeds.2012.11.070Stagi S, Municchi G, Ferrari M, Wasniewska MG. An overview on different l-thyroxine (l-t4) formulations and factors potentially influencing the treatment of congenital hypothyroidism during the first 3 years of life. Front Endocrinol (Lausanne). 2022;(13):1-19. doi: https://doi.org/10.3389/fendo.2022.859487Stagi S, Municchi G, Ferrari M, Wasniewska MG. An overview on different l-thyroxine (l-t4) formulations and factors potentially influencing the treatment of congenital hypothyroidism during the first 3 years of life. Front Endocrinol (Lausanne). 2022;(13):1-19. doi: https://doi.org/10.3389/fendo.2022.859487Yue C, Scarsi C, Ducharme M. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung. 2012;62(12):631-636. doi: https://doi.org/10.1055/s-0032-1329951Yue C, Scarsi C, Ducharme M. Pharmacokinetics and potential advantages of a new oral solution of levothyroxine vs. other available dosage forms. Arzneimittelforschung. 2012;62(12):631-636. doi: https://doi.org/10.1055/s-0032-1329951Cappelli C, Pirola I, Daffini L, et al. A double-blind placebocontrolled trial of liquid thyroxine ingested at breakfast: Results of the TICO study. Thyroid. 2016;26(2):197-202. doi: https://doi.org/10.1089/thy.2015.0422Cappelli C, Pirola I, Daffini L, et al. A double-blind placebocontrolled trial of liquid thyroxine ingested at breakfast: Results of the TICO study. Thyroid. 2016;26(2):197-202. doi: https://doi.org/10.1089/thy.2015.0422Pirola I, Gandossi E, Brancato D, et al. TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast. J Endocrinol Invest. 2018;41(11):1301-1306. doi: https://doi.org/10.1007/s40618-018-0867-3Pirola I, Gandossi E, Brancato D, et al. TSH evaluation in hypothyroid patients assuming liquid levothyroxine at breakfast or 30 min before breakfast. J Endocrinol Invest. 2018;41(11):1301-1306. doi: https://doi.org/10.1007/s40618-018-0867-3Ducharme M, Scarsi C, Bettazzi E, Mautone G, Lewis Y, Celi FS. A Novel Levothyroxine Solution Results in Similar Bioavailability Whether Taken 30 or Just 15 Minutes before a High-Fat High-Calorie Meal. Thyroid. 2022;32(8):897-904. doi: https://doi.org/10.1089/thy.2021.0604Ducharme M, Scarsi C, Bettazzi E, Mautone G, Lewis Y, Celi FS. A Novel Levothyroxine Solution Results in Similar Bioavailability Whether Taken 30 or Just 15 Minutes before a High-Fat High-Calorie Meal. Thyroid. 2022;32(8):897-904. doi: https://doi.org/10.1089/thy.2021.0604Vita R, Saraceno G, Trimarchi F, Benvenga S. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by protonpump inhibitors. J Clin Endocrinol Metab. 2014;99(12):4481-4486. doi: https://doi.org/10.1210/jc.2014-2684Vita R, Saraceno G, Trimarchi F, Benvenga S. Switching levothyroxine from the tablet to the oral solution formulation corrects the impaired absorption of levothyroxine induced by protonpump inhibitors. J Clin Endocrinol Metab. 2014;99(12):4481-4486. doi: https://doi.org/10.1210/jc.2014-2684Benvenga S, Di Bari F, Vita R. Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine. Endocrine. 2017;56(1):138-145. doi: https://doi.org/10.1007/s12020-017-1244-2Benvenga S, Di Bari F, Vita R. Undertreated hypothyroidism due to calcium or iron supplementation corrected by oral liquid levothyroxine. Endocrine. 2017;56(1):138-145. doi: https://doi.org/10.1007/s12020-017-1244-2Vita R, Di Bari F, Benvenga S. Oral liquid levothyroxine solves the problem of tablet levothyroxine malabsorption due to concomitant intake of multiple drugs. Expert Opin Drug Deliv. 2017;14(4):467-472. doi: https://doi.org/10.1080/17425247.2017.1290604Vita R, Di Bari F, Benvenga S. Oral liquid levothyroxine solves the problem of tablet levothyroxine malabsorption due to concomitant intake of multiple drugs. Expert Opin Drug Deliv. 2017;14(4):467-472. doi: https://doi.org/10.1080/17425247.2017.1290604Tortora A, La Sala D, Vitale M. Switch from tablet levothyroxine to oral solution resolved reduced absorption by intestinal parasitosis. Endocrinol Diabetes Metab Case Reports. 2019;2019(12):631-636. doi: https://doi.org/10.1530/EDM-19-0026Tortora A, La Sala D, Vitale M. Switch from tablet levothyroxine to oral solution resolved reduced absorption by intestinal parasitosis. Endocrinol Diabetes Metab Case Reports. 2019;2019(12):631-636. doi: https://doi.org/10.1530/EDM-19-0026Ribichini D, Fiorini G, Repaci A, et al. Tablet and oral liquid L-thyroxine formulation in the treatment of naïve hypothyroid patients with Helicobacter pylori infection. Endocrine. 2017;57(3):394-401. doi: https://doi.org/10.1007/s12020-016-1167-3Ribichini D, Fiorini G, Repaci A, et al. Tablet and oral liquid L-thyroxine formulation in the treatment of naïve hypothyroid patients with Helicobacter pylori infection. Endocrine. 2017;57(3):394-401. doi: https://doi.org/10.1007/s12020-016-1167-3Fallahi P, Ferrari SM, Ruffilli I, Antonelli A. Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: A case series. BMC Gastroenterol. 2016;16(1):1-5. doi: https://doi.org/10.1186/s12876-016-0439-yFallahi P, Ferrari SM, Ruffilli I, Antonelli A. Reversible normalisation of serum TSH levels in patients with autoimmune atrophic gastritis who received L-T4 in tablet form after switching to an oral liquid formulation: A case series. BMC Gastroenterol. 2016;16(1):1-5. doi: https://doi.org/10.1186/s12876-016-0439-yFallahi P, Ferrari SM, Marchi S, et al. Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine. Endocrine. 2017;57(1):175-178. doi: https://doi.org/10.1007/s12020-016-1090-7Fallahi P, Ferrari SM, Marchi S, et al. Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine. Endocrine. 2017;57(1):175-178. doi: https://doi.org/10.1007/s12020-016-1090-7Benvenga S, Capodicasa G, Perelli S, et al. Increased requirement of replacement doses of levothyroxine caused by liver cirrhosis. Front Endocrinol (Lausanne). 2018;(9):1-5. doi: https://doi.org/10.3389/fendo.2018.00150Benvenga S, Capodicasa G, Perelli S, et al. Increased requirement of replacement doses of levothyroxine caused by liver cirrhosis. Front Endocrinol (Lausanne). 2018;(9):1-5. doi: https://doi.org/10.3389/fendo.2018.00150Hommel C, Delgrange E. Resistance to levothyroxine in a bariatric surgery patient: an indication for liquid formulation? Acta Clin Belgica Int J Clin Lab Med. 2017;72(1):72-75. doi: https://doi.org/10.1080/17843286.2016.1196861Hommel C, Delgrange E. Resistance to levothyroxine in a bariatric surgery patient: an indication for liquid formulation? Acta Clin Belgica Int J Clin Lab Med. 2017;72(1):72-75. doi: https://doi.org/10.1080/17843286.2016.1196861Bornikowska K, Gietka-Czernel M, Raczkiewicz D, et al. Improvements in quality of life and thyroid parameters in hypothyroid patients on ethanol-free formula of liquid levothyroxine therapy in comparison to tablet LT4 form: An observational study. J Clin Med. 2021;10(22):5233. doi: https://doi.org/10.3390/jcm10225233Bornikowska K, Gietka-Czernel M, Raczkiewicz D, et al. Improvements in quality of life and thyroid parameters in hypothyroid patients on ethanol-free formula of liquid levothyroxine therapy in comparison to tablet LT4 form: An observational study. J Clin Med. 2021;10(22):5233. doi: https://doi.org/10.3390/jcm10225233Henderson BB. Levothyroxine sodium oral solution normalizes thyroid function in a patient with hashimoto’s disease, gastritis, diabetic gastroparesis, and small intestinal bacterial overgrowth (Sibo). Int Med Case Rep J. 2021;14(22):627-632. doi: https://doi.org/10.2147/IMCRJ.S326481Henderson BB. Levothyroxine sodium oral solution normalizes thyroid function in a patient with hashimoto’s disease, gastritis, diabetic gastroparesis, and small intestinal bacterial overgrowth (Sibo). Int Med Case Rep J. 2021;14(22):627-632. doi: https://doi.org/10.2147/IMCRJ.S326481Virili C, Giovanella L, Fallahi P, et al. Levothyroxine therapy: Changes of TSH levels by switching patients from tablet to liquid formulation. A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2018;(9):1-6. doi: https://doi.org/10.3389/fendo.2018.00010Virili C, Giovanella L, Fallahi P, et al. Levothyroxine therapy: Changes of TSH levels by switching patients from tablet to liquid formulation. A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2018;(9):1-6. doi: https://doi.org/10.3389/fendo.2018.00010Laurent I, Tang S, Astère M, et al. Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis. Endocrine. 2018;61(1):28-35. doi: https://doi.org/10.1007/s12020-018-1574-8Laurent I, Tang S, Astère M, et al. Liquid L-thyroxine versus tablet L-thyroxine in patients on L- thyroxine replacement or suppressive therapy: a meta-analysis. Endocrine. 2018;61(1):28-35. doi: https://doi.org/10.1007/s12020-018-1574-8Ferrara R, Ientile V, Arcoraci V, et al. Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009–2015. Endocrine. 2017;58(1):143-152. doi: https://doi.org/10.1007/s12020-017-1242-4Ferrara R, Ientile V, Arcoraci V, et al. Treatment pattern and frequency of serum TSH measurement in users of different levothyroxine formulations: a population-based study during the years 2009–2015. Endocrine. 2017;58(1):143-152. doi: https://doi.org/10.1007/s12020-017-1242-4Cappelli C, Negro R, Pirola I, et al. Levothyroxine liquid solution versus tablet form for replacement treatment in pregnant women. Gynecol Endocrinol. 2016;32(4):290-292. doi: https://doi.org/10.3109/09513590.2015.1113518Cappelli C, Negro R, Pirola I, et al. Levothyroxine liquid solution versus tablet form for replacement treatment in pregnant women. Gynecol Endocrinol. 2016;32(4):290-292. doi: https://doi.org/10.3109/09513590.2015.1113518Guglielmi R, Grimaldi F, Negro R, et al. Shift from levothyroxine tablets to liquid formulation at breakfast improves quality of life of hypothyroid patients. Endocrine, Metab Immune Disord - Drug Targets. 2018;18(3):235-240. doi: https://doi.org/10.2174/1871530318666180125155348Guglielmi R, Grimaldi F, Negro R, et al. Shift from levothyroxine tablets to liquid formulation at breakfast improves quality of life of hypothyroid patients. Endocrine, Metab Immune Disord - Drug Targets. 2018;18(3):235-240. doi: https://doi.org/10.2174/1871530318666180125155348Cappelli C, Pirola I, Gandossi E, et al. Thyroid Hormone Profile in Patients Ingesting Soft Gel Capsule or Liquid Levothyroxine Formulations with Breakfast. Int J Endocrinol. 2016;2016:1-5. doi: https://doi.org/10.1155/2016/9043450Cappelli C, Pirola I, Gandossi E, et al. Thyroid Hormone Profile in Patients Ingesting Soft Gel Capsule or Liquid Levothyroxine Formulations with Breakfast. Int J Endocrinol. 2016;2016:1-5. doi: https://doi.org/10.1155/2016/9043450Peirce C, Ippolito S, Lanas A, et al. Treatment of refractory and severe hypothyroidism with sublingual levothyroxine in liquid formulation. Endocrine. 2018;60(1):193-196. doi: https://doi.org/10.1007/s12020-017-1367-5Peirce C, Ippolito S, Lanas A, et al. Treatment of refractory and severe hypothyroidism with sublingual levothyroxine in liquid formulation. Endocrine. 2018;60(1):193-196. doi: https://doi.org/10.1007/s12020-017-1367-5Giusti M, Mortara L, Machello N, et al. Utility of a liquid formulation of levo-thyroxine in differentiated thyroid cancer patients. Drug Res (Stuttg). 2014;65(6):332-336. doi: https://doi.org/10.1055/s-0034-1384535Giusti M, Mortara L, Machello N, et al. Utility of a liquid formulation of levo-thyroxine in differentiated thyroid cancer patients. Drug Res (Stuttg). 2014;65(6):332-336. doi: https://doi.org/10.1055/s-0034-1384535Kaur N, Suryanarayanan R. Levothyroxine sodium pentahydrate tablets — formulation considerations. J Pharm Sci. 2021;110(12):3743-3756. doi: https://doi.org/10.1016/j.xphs.2021.08.006Kaur N, Suryanarayanan R. Levothyroxine sodium pentahydrate tablets — formulation considerations. J Pharm Sci. 2021;110(12):3743-3756. doi: https://doi.org/10.1016/j.xphs.2021.08.006Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm. 2009;72(1):105-110. doi: https://doi.org/10.1016/j.ejpb.2008.10.008Pabla D, Akhlaghi F, Zia H. A comparative pH-dissolution profile study of selected commercial levothyroxine products using inductively coupled plasma mass spectrometry. Eur J Pharm Biopharm. 2009;72(1):105-110. doi: https://doi.org/10.1016/j.ejpb.2008.10.008Trimboli P, Scappaticcio L, De Bellis A, et al. Different formulations of levothyroxine for treating hypothyroidism: A real-life study. Int J Endocrinol. 2020;2020:1-5. doi: https://doi.org/10.1155/2020/4524759Trimboli P, Scappaticcio L, De Bellis A, et al. Different formulations of levothyroxine for treating hypothyroidism: A real-life study. Int J Endocrinol. 2020;2020:1-5. doi: https://doi.org/10.1155/2020/4524759Vita R, Saraceno G, Trimarchi F, Benvenga S. A novel formulation of l-thyroxine (l-T4) reduces the problem of l-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine. 2013;43(1):154-160. doi: https://doi.org/10.1007/s12020-012-9772-2Vita R, Saraceno G, Trimarchi F, Benvenga S. A novel formulation of l-thyroxine (l-T4) reduces the problem of l-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine. 2013;43(1):154-160. doi: https://doi.org/10.1007/s12020-012-9772-2Santaguida MG, Virili C, Duca SC Del, et al. Thyroxine softgel capsule in patients with gastric-related T4 malabsorption. Endocrine. 2015;49(1):51-57. doi: https://doi.org/10.1007/s12020-014-0476-7Santaguida MG, Virili C, Duca SC Del, et al. Thyroxine softgel capsule in patients with gastric-related T4 malabsorption. Endocrine. 2015;49(1):51-57. doi: https://doi.org/10.1007/s12020-014-0476-7Kim PJ, Sachmechi I. Levothyroxine malabsorption induced by diabetic gastroparesis exacerbated during pregnancies: Effect of intramuscular levothyroxine injections and levothyroxine soft gel capsules. AACE Clin Case Reports. 2015;1(1):e73-e78. doi: https://doi.org/10.4158/EP14051.CRKim PJ, Sachmechi I. Levothyroxine malabsorption induced by diabetic gastroparesis exacerbated during pregnancies: Effect of intramuscular levothyroxine injections and levothyroxine soft gel capsules. AACE Clin Case Reports. 2015;1(1):e73-e78. doi: https://doi.org/10.4158/EP14051.CRReardon DP, Yoo PS. Levothyroxine tablet malabsorption associated with gastroparesis corrected with gelatin capsule formulation. Case Rep Endocrinol. 2016;2016(1):1-3. doi: https://doi.org/10.1155/2016/1316724Reardon DP, Yoo PS. Levothyroxine tablet malabsorption associated with gastroparesis corrected with gelatin capsule formulation. Case Rep Endocrinol. 2016;2016(1):1-3. doi: https://doi.org/10.1155/2016/1316724Di Donna V, Paragliola RM, de Waure C, et al. Is levothyroxine requirement the same for tablet and soft gel formulations? Endocrine. 2018;59(2):458-460. doi: https://doi.org/10.1007/s12020-017-1311-8Di Donna V, Paragliola RM, de Waure C, et al. Is levothyroxine requirement the same for tablet and soft gel formulations? Endocrine. 2018;59(2):458-460. doi: https://doi.org/10.1007/s12020-017-1311-8Benvenga S, Capodicasa G, Perelli S. l-Thyroxine in an oral liquid or softgel formulation ensures more normal serum levels of free T4 in patients with central hypothyroidism. Front Endocrinol (Lausanne). 2017;8(1):e73-e78. doi: https://doi.org/10.3389/fendo.2017.00321Benvenga S, Capodicasa G, Perelli S. l-Thyroxine in an oral liquid or softgel formulation ensures more normal serum levels of free T4 in patients with central hypothyroidism. Front Endocrinol (Lausanne). 2017;8(1):e73-e78. doi: https://doi.org/10.3389/fendo.2017.00321Ernst FR, Sandulli W, Elmor R, et al. Retrospective study of patients switched from tablet formulations to a gel cap formulation of levothyroxine: Results of the CONTROL switch study. Drugs RD. 2017;17(1):103-115. doi: https://doi.org/10.1007/s40268-016-0150-zErnst FR, Sandulli W, Elmor R, et al. Retrospective study of patients switched from tablet formulations to a gel cap formulation of levothyroxine: Results of the CONTROL switch study. Drugs RD. 2017;17(1):103-115. doi: https://doi.org/10.1007/s40268-016-0150-zKashanian S, Rostami E. PEG-stearate coated solid lipid nanoparticles as levothyroxine carriers for oral administration. J Nanoparticle Res. 2014;16(3):2293. doi: https://doi.org/10.1007/s11051-014-2293-6Kashanian S, Rostami E. PEG-stearate coated solid lipid nanoparticles as levothyroxine carriers for oral administration. J Nanoparticle Res. 2014;16(3):2293. doi: https://doi.org/10.1007/s11051-014-2293-6Parhi R, Suresh P. Production of solid lipid nanoparticles-drug loading and release mechanism. J Chem Pharmacuetical Res. 2010;2(1):211-227.Parhi R, Suresh P. Production of solid lipid nanoparticles-drug loading and release mechanism. J Chem Pharmacuetical Res. 2010;2(1):211-227.Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspective. Int J Nanomedicine. 2007;2(3):289-300.Üner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspective. Int J Nanomedicine. 2007;2(3):289-300.Cavalli R, Gasco MR, Chetoni P, et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002;238(1-2):241-245. doi: https://doi.org/10.1016/S0378-5173(02)00080-7Cavalli R, Gasco MR, Chetoni P, et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002;238(1-2):241-245. doi: https://doi.org/10.1016/S0378-5173(02)00080-7FDA [Internet]. Levothyroxine sodium for injection; 2011 [cited 24.07.2023]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202231s000lbl.pdfFDA [Internet]. Levothyroxine sodium for injection; 2011 [cited 24.07.2023]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202231s000lbl.pdfNakano Y, Hashimoto K, Ohkiba N, et al. A case of refractory hypothyroidism due to poor compliance treated with the weekly intravenous and oral levothyroxine administration. Case Rep Endocrinol. 2019;2019:1-6. doi: https://doi.org/10.1155/2019/5986014Nakano Y, Hashimoto K, Ohkiba N, et al. A case of refractory hypothyroidism due to poor compliance treated with the weekly intravenous and oral levothyroxine administration. Case Rep Endocrinol. 2019;2019:1-6. doi: https://doi.org/10.1155/2019/5986014Peynirci H, Taskiran B, Erturk E, et al. Is parenteral levothyroxine therapy safe in intractable hypothyroidism? J Natl Med Assoc. 2018;110(3):245-249. doi: https://doi.org/10.1016/j.jnma.2017.05.007Peynirci H, Taskiran B, Erturk E, et al. Is parenteral levothyroxine therapy safe in intractable hypothyroidism? J Natl Med Assoc. 2018;110(3):245-249. doi: https://doi.org/10.1016/j.jnma.2017.05.007Garayalde Gamboa MDLÁ, Saban M, Curriá MI. Treatment with intramuscular levothyroxine in refractory hypothyroidism. Eur Thyroid J. 2019;8(6):319-323. doi: https://doi.org/10.1159/000503324Garayalde Gamboa MDLÁ, Saban M, Curriá MI. Treatment with intramuscular levothyroxine in refractory hypothyroidism. Eur Thyroid J. 2019;8(6):319-323. doi: https://doi.org/10.1159/000503324Kashanian S, Rostami E, Harding FJ, et al. Controlled delivery of levothyroxine using porous silicon as a drug nanocontainer. Aust J Chem. 2016;69(2):204-211. doi: https://doi.org/10.1071/CH15315Kashanian S, Rostami E, Harding FJ, et al. Controlled delivery of levothyroxine using porous silicon as a drug nanocontainer. Aust J Chem. 2016;69(2):204-211. doi: https://doi.org/10.1071/CH15315Kamali H, Khodaverdi E, Hadizadeh F, et al. An in-situ forming implant formulation of naltrexone with minimum initial burst release using mixture of PLGA copolymers and ethyl heptanoate as an additive: In-vitro, ex-vivo, and in-vivo release evaluation. J Drug Deliv Sci Technol. 2018;47:95-105. doi: https://doi.org/10.1016/j.jddst.2018.06.027Kamali H, Khodaverdi E, Hadizadeh F, et al. An in-situ forming implant formulation of naltrexone with minimum initial burst release using mixture of PLGA copolymers and ethyl heptanoate as an additive: In-vitro, ex-vivo, and in-vivo release evaluation. J Drug Deliv Sci Technol. 2018;47:95-105. doi: https://doi.org/10.1016/j.jddst.2018.06.027Mashayekhi R, Mobedi H, Najafi J, Enayati M. In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga system. DARU J Pharm Sci. 2013;21(1):57. doi: https://doi.org/10.1186/2008-2231-21-57Mashayekhi R, Mobedi H, Najafi J, Enayati M. In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga system. DARU J Pharm Sci. 2013;21(1):57. doi: https://doi.org/10.1186/2008-2231-21-57Padula C, Nicoli S, Santi P. Innovative formulations for the delivery of levothyroxine to the skin. Int J Pharm. 2009;372(1-2):12-16. doi: https://doi.org/10.1016/j.ijpharm.2008.12.028Padula C, Nicoli S, Santi P. Innovative formulations for the delivery of levothyroxine to the skin. Int J Pharm. 2009;372(1-2):12-16. doi: https://doi.org/10.1016/j.ijpharm.2008.12.028Azarbayjani AF, Venugopal JR, Ramakrishna S, et al. Smart polymeric nanofibers for topical delivery of levothyroxine. J Pharm Pharm Sci. 2010;13(3):400-410. doi: https://doi.org/10.18433/j3ts3gAzarbayjani AF, Venugopal JR, Ramakrishna S, et al. Smart polymeric nanofibers for topical delivery of levothyroxine. J Pharm Pharm Sci. 2010;13(3):400-410. doi: https://doi.org/10.18433/j3ts3gYbarra M, Dos Santos TJ, Pinheiro CTC, et al. Rectal levothyroxine for the treatment of hypothyroidism: A case study. Pediatrics. 2018;142(2):e20173317. doi: https://doi.org/10.1542/peds.2017-3317Ybarra M, Dos Santos TJ, Pinheiro CTC, et al. Rectal levothyroxine for the treatment of hypothyroidism: A case study. Pediatrics. 2018;142(2):e20173317. doi: https://doi.org/10.1542/peds.2017-3317Kashiwagura Y, Uchida S, Tanaka S, et al. Clinical efficacy and pharmacokinetics of levothyroxine suppository in patients with hypothyroidism. Biol Pharm Bull. 2014;37(4):666-670. doi: https://doi.org/10.1248/bpb.b13-00998Kashiwagura Y, Uchida S, Tanaka S, et al. Clinical efficacy and pharmacokinetics of levothyroxine suppository in patients with hypothyroidism. Biol Pharm Bull. 2014;37(4):666-670. doi: https://doi.org/10.1248/bpb.b13-00998Obeidat KA, Saadeh NA, As’ad A, Bakkar S. Successful management of hypothyroidism in gastric outlet obstruction using levothyroxine rectal enemas: A case report. Am J Case Rep. 2018;19(1):903-905. doi: https://doi.org/10.12659/AJCR.909437Obeidat KA, Saadeh NA, As’ad A, Bakkar S. Successful management of hypothyroidism in gastric outlet obstruction using levothyroxine rectal enemas: A case report. Am J Case Rep. 2018;19(1):903-905. doi: https://doi.org/10.12659/AJCR.909437Grijota-Martínez C, Bárez-López S, Ausó E, et al. Intranasal delivery of thyroid hormones in MCT8 deficiency. PLoS One. 2020;15(7):1-14. doi: https://doi.org/10.1371/journal.pone.0236113Grijota-Martínez C, Bárez-López S, Ausó E, et al. Intranasal delivery of thyroid hormones in MCT8 deficiency. PLoS One. 2020;15(7):1-14. doi: https://doi.org/10.1371/journal.pone.0236113Flores-Huerta S, Hernández-Montes H, Argote RM, Villalpando S. Effects of ethanol consumption during pregnancy and lactation on the outcome and postnatal growth of the offspring. Ann Nutr Metab. 1992;36(3):121-128. doi: https://doi.org/10.1159/000177706Flores-Huerta S, Hernández-Montes H, Argote RM, Villalpando S. Effects of ethanol consumption during pregnancy and lactation on the outcome and postnatal growth of the offspring. Ann Nutr Metab. 1992;36(3):121-128. doi: https://doi.org/10.1159/000177706Messina E, Ferraù F, Cannavò S. Oral mucositis induced by treatment with soft gel formulation of levothyroxine. Endocrine. 2018;59(1):226-227. doi: https://doi.org/10.1007/s12020-017-1312-7Messina E, Ferraù F, Cannavò S. Oral mucositis induced by treatment with soft gel formulation of levothyroxine. Endocrine. 2018;59(1):226-227. doi: https://doi.org/10.1007/s12020-017-1312-7Lehnert H, Castello-Bridoux C, Channaiah B, et al. Comparison of safety profiles of the new and old formulations of levothyroxine in a first global introduction in France. Exp Clin Endocrinol Diabetes. 2021;129(12):908-917. doi: https://doi.org/10.1055/a-1302-9343Lehnert H, Castello-Bridoux C, Channaiah B, et al. Comparison of safety profiles of the new and old formulations of levothyroxine in a first global introduction in France. Exp Clin Endocrinol Diabetes. 2021;129(12):908-917. doi: https://doi.org/10.1055/a-1302-9343Nagy EV, Perros P, Papini E, et al. New formulations of levothyroxine in the treatment of hypothyroidism: trick or treat? Thyroid. 2021;31(2):193-201. doi: https://doi.org/10.1089/thy.2020.0515Nagy EV, Perros P, Papini E, et al. New formulations of levothyroxine in the treatment of hypothyroidism: trick or treat? Thyroid. 2021;31(2):193-201. doi: https://doi.org/10.1089/thy.2020.0515

The authors declare that there are no conflicts of interest present.